drugset / Trial / NCT02117024
A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
Determine whether viagenpumatucel-L combined with low-dose cyclophosphamide prolongs survival in patients with NSCLC who failed 2 or 3 prior lines of therapy for incurable or metastatic disease compared with chemotherapy alone.
Timeline
- Start
- 2014-07
- Primary completion
- 2017-12
- Completion
- 2018-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 50 mg | Oral |
| Comparator | Docetaxel | Small molecule | — | — |
| Comparator | Erlotinib | Small molecule | — | — |
| Comparator | Gemcitabine | Small molecule | — | — |
| Comparator | Paclitaxel | Small molecule | — | — |
| Comparator | Pemetrexed | Small molecule | — | — |
| Subject | Viagenpumatucel-L | Vaccine | 1e+07 cells | Other |
| Comparator | Vinorelbine | Small molecule | — | — |